肺动脉高压治疗药物司来帕格

Selexipag in the treatment of pulmonary arterial hypertension

肺动脉高压是一类肺动脉压力和肺血管阻力进行性升高,最终可致右心功能衰竭和患者死亡的预后极差的恶性心血管系统疾病。近年来,靶向治疗药物的应用大大改善了肺动脉高压患者的症状与预后。其中,司来帕格作为第一种获准上市的口服前列环素受体激动剂,其在肺动脉高压治疗中的作用越来越受到重视。本文就司来帕格的作用机制、药代动力学、临床研究和应用现况作一概要介绍。

Pulmonary arterial hypertension is a kind of malignant cardiovascular disease characterized by progressive increase of pulmonary artery pressure and pulmonary vascular resistance,which eventually leads to right heart failure and death.In recent years,targeted drugs have greatly improved the symptoms and prognosis of patients with pulmonary arterial hypertension.Selexipag,as the first approved oral prostacyclin receptor agonist,more and more attention has been paid to.In this paper,the mechanism,pharmacokinetics and clinical application of selexipag are reviewed.